EKSO vs MYO vs IRBT vs GMED vs NVCR

For growth investors, Myomo, Inc.

(MYO) is the stronger pick with 25. 7% revenue growth year-over-year, versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). Globus Medical, Inc. (GMED) offers the better valuation at 21. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Ekso Bionics Holdings, Inc. (EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Globus Medical, Inc.

(GMED) delivered a total return of +16. 1%, compared to -99. 9% for iRobot Corporation (IRBT). Over 10 years, the gap is even starker: GMED returned +264. 4% versus IRBT's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Globus Medical, Inc.

(GMED) is the lower-risk stock at 1. 29β versus iRobot Corporation's 5. 21β — meaning IRBT is approximately 305% more volatile than GMED relative to the S&P 500. On balance sheet safety, Globus Medical, Inc. (GMED) carries a lower debt/equity ratio of 3% versus 4% for iRobot Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Myomo, Inc.

(MYO) is pulling ahead at 25. 7% versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Globus Medical, Inc.

(GMED) is the more profitable company, earning 18. 3% net margin versus -91. 4% for Ekso Bionics Holdings, Inc. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMED leads at 16. 3% versus -104. 1% for EKSO. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

In this comparison, EKSO (0.

8% yield) pays a dividend. MYO, IRBT, GMED, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Globus Medical, Inc.

(GMED) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29), +264. 4% 10Y return). iRobot Corporation (IRBT) carries a higher beta of 5. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GMED: +264. 4%, IRBT: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EKSO (Healthcare) and MYO (Healthcare) and IRBT (Consumer Cyclical) and GMED (Healthcare) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EKSO is a small-cap quality compounder stock; MYO is a small-cap high-growth stock; IRBT is a small-cap quality compounder stock; GMED is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock. EKSO pays a dividend while MYO, IRBT, GMED, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.